FBLG

Company Overview — What Does FibroBiologics, Inc. Do?

We are a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and for potential extension of life applications including thymic and splenic involution reversal. In connection with our formation, we issued shares of our Series A Preferred Stock, or the Series A Preferred Stock, to our then parent, SpinalCyte LLC (doing business as FibroGenesis), or FibroGenesis, in return for rights to certain intellectual property through a patent assignment agreement and an intellectual property cross-licensing agreement. Developing the intellectual property obtained from FibroGenesis was the basis for our formation. Prior to our inception, preclinical research and development related to the transferred intellectual property took place under FibroGenesis. Fibroblasts Technology Platform Fibroblasts and stem cells are the only two cell types in the human body that can regenerate tissue and organs. Studies have indicated that mesenchymal stem cells and fibroblasts share many surface markers in common, and can differentiate into many cells including adipocytes, chondrocytes, osteoblasts, hepatocytes, and cardiomyocytes, and can regulate the immune system. However, transcriptomic and epigenetic studies have indicated a clear difference between the two cell types. Fibroblasts comprise the main cell type of connective tissue, possessing a spindle-shaped morphology, whose classical function has historically been believed to produce an extracellular matrix responsible for maintaining the structural integrity of the tissue. Fibroblasts also play an important role in maintaining stem cell niches in organs and are involved in every stage of wound healing. Fibroblasts are favorable to stem cells as a cell therapy treatment platform because fibroblasts: . can be non-invasively harvested from a variety of skin donors from surgical procedures such as tummy tuck flaps or simple biopsy punch; . have a faster doubling time in culture than stem cells; . possess superior immune modulatory activity compared with stem cells; . exhibit enhanced ability to produce regenerative cytokines and growth factors compared with stem cells; and . are more economical to isolate, culture and expand compared with stem cells because fibroblasts do not require the use of expensive tissue culture media and additives. Studies have demonstrated that allogeneic fibroblasts, much like mesenchymal stem cells, are immune-privileged and do not provoke an immune response in vitro and in vivo. If autologous fibroblasts were required instead, it would mean that cells would have to be harvested from each patient, processed and cultured, and then administered to the same patient, which would be more costly and inefficient. Because allogeneic fibroblasts do not cause an immune response, we are planning to build our own current Good Manufacturing Practices, or cGMP, manufacturing facility to source allogeneic fibroblast cells for clinical testing of our product candidates and for commercial sales if our product candidates receive marketing approval. To date, however, no fibroblast therapy products have been approved and there have only been a few clinical trials involving fibroblasts. The costs to develop, manufacture, and commercialize product candidates utilizing our fibroblasts technology platform may exceed our estimates. Furthermore, the biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates so any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We were formed in April 2021 as a Texas limited liability company under the name FibroBiologics, LLC, and converted to a Delaware corporation in December 2021 under the name Fibrobiologics, Inc. On April 12, 2023, we changed our name to FibroBiologics, Inc. Our principal executive offices are located at 455 E. Medical Center Blvd., Suite 300, Houston, Texas. FibroBiologics, Inc. (FBLG) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Pete O’Heeron, headquartered in HOUSTON, Texas. With a market capitalization of $5M, FBLG is one of the notable companies in the Healthcare sector.

FibroBiologics, Inc. (FBLG) Stock Rating — Reduce (April 2026)

As of April 2026, FibroBiologics, Inc. receives a Reduce rating with a composite score of 23.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.FBLG ranks #3,284 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, FibroBiologics, Inc. ranks #499 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

FBLG Stock Price and 52-Week Range

FibroBiologics, Inc. (FBLG) currently trades at $1.39. The stock gained $0.01 (0.7%) in the most recent trading session. The 52-week high for FBLG is $1.53, which means the stock is currently trading -9.2% from its annual peak. The 52-week low is $0.22, putting the stock 531.3% above its annual trough. Recent trading volume was 346K shares, suggesting relatively thin trading activity.

Is FBLG Overvalued or Undervalued? — Valuation Analysis

FibroBiologics, Inc. (FBLG) carries a value factor score of 7/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.05x, versus the sector average of 2.75x.

At current multiples, FibroBiologics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

FibroBiologics, Inc. Profitability — ROE, Margins, and Quality Score

FibroBiologics, Inc. (FBLG) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -258.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -165.3% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

FBLG Debt, Balance Sheet, and Financial Health

FibroBiologics, Inc. has a debt-to-equity ratio of 56.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.61x, indicating strong short-term liquidity. Total debt on the balance sheet is $5M. Cash and equivalents stand at $5M.

FBLG has a beta of 5.25, meaning it is more volatile than the broader market — a $10,000 investment in FBLG would be expected to move 425.1% more than the S&P 500 on any given day. The stability factor score for FibroBiologics, Inc. is 3/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

FibroBiologics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, FibroBiologics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.42. Net income for the quarter was $-16M. Operating income came in at $-17M.

In FY 2025, FibroBiologics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.42. Net income for the quarter was $-19M. Operating income came in at $-17M.

In Q3 2025, FibroBiologics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.13. Net income for the quarter was $-6M. Operating income came in at $-5M.

In Q2 2025, FibroBiologics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.12. Net income for the quarter was $-5M. Operating income came in at $-4M.

Over the past 8 quarters, FibroBiologics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing FBLG stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

FBLG Dividend Yield and Income Analysis

FibroBiologics, Inc. (FBLG) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

FBLG Momentum and Technical Analysis Profile

FibroBiologics, Inc. (FBLG) has a momentum factor score of 43/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 20/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

FBLG vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, FibroBiologics, Inc. (FBLG) ranks #499 out of 838 stocks based on the Blank Capital composite score. This places FBLG in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing FBLG against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full FBLG vs S&P 500 (SPY) comparison to assess how FibroBiologics, Inc. stacks up against the broader market across all factor dimensions.

FBLG Next Earnings Date

No upcoming earnings date has been announced for FibroBiologics, Inc. (FBLG) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy FBLG? — Investment Thesis Summary

The quantitative profile for FibroBiologics, Inc. suggests caution. The quality score of 24/100 flags below-average profitability. The value score of 7/100 indicates premium valuation. High volatility (stability score 3/100) increases portfolio risk.

In summary, FibroBiologics, Inc. (FBLG) earns a Reduce rating with a composite score of 23.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on FBLG stock.

Related Resources for FBLG Investors

Explore more research and tools: FBLG vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare FBLG head-to-head with peers: FBLG vs AZN, FBLG vs SLGL, FBLG vs VMD.